They found that the response rate was significantly lower among patients who had PD-L1 negative and poorly proliferated tumours (6.5%) than among those with PD-L1 negative and moderately proliferative tumours (30%).

The findings are preliminary because of the small number of patients included in the study. More research is needed to determine whether the 2 measures could be used as biomarkers in practice.

Read more in Cancer Therapy Advisor here